As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to enhance healthcare delivery.

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

Moderna MRNA0.58%increase; green up pointing triangle set financial targets for 2025 as companies in the healthcare space rolled out corporate updates in conjunction with a health conference held ...

The pandemic accelerated Moderna's evolution into a commercial-stage biotech, and we expect that the firm's ramp-up in manufacturing and clinical know-how will pave the way for faster timelines ...

Shares plunge more than 24% in early trading 2025 revenue forecast misses expectations, prior view CEO Bancel says to reduce 2025 cash costs by $1 bln Jan 13 (Reuters) - Moderna (MRNA.O), opens ...

Jan. 18 (UPI) --Georgia officials on Friday halted all in-state poultry sales, and the U.S. Department of Health and Human Services awarded $590 million to Moderna to accelerate development of ...

US vaccines developer Moderna today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine ...